[go: up one dir, main page]

NO179164C - Fremgangsmåte for fremstilling av et immunogenkonjugat - Google Patents

Fremgangsmåte for fremstilling av et immunogenkonjugat

Info

Publication number
NO179164C
NO179164C NO902909A NO902909A NO179164C NO 179164 C NO179164 C NO 179164C NO 902909 A NO902909 A NO 902909A NO 902909 A NO902909 A NO 902909A NO 179164 C NO179164 C NO 179164C
Authority
NO
Norway
Prior art keywords
conjugates
epitopes
preparing
immunogen conjugate
antigens
Prior art date
Application number
NO902909A
Other languages
English (en)
Other versions
NO902909D0 (no
NO179164B (no
NO902909L (no
Inventor
Garvin Bixler
Subramonia Pillai
Richard Insel
Original Assignee
American Cyanamid Co
Praxis Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co, Praxis Biolog Inc filed Critical American Cyanamid Co
Publication of NO902909D0 publication Critical patent/NO902909D0/no
Publication of NO902909L publication Critical patent/NO902909L/no
Publication of NO179164B publication Critical patent/NO179164B/no
Publication of NO179164C publication Critical patent/NO179164C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Optical Couplings Of Light Guides (AREA)
NO902909A 1988-02-01 1990-06-29 Fremgangsmåte for fremstilling av et immunogenkonjugat NO179164C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15068888A 1988-02-01 1988-02-01
PCT/US1989/000388 WO1989006974A2 (en) 1988-02-01 1989-01-31 T-cell epitope as carriers molecule for conjugate vaccines

Publications (4)

Publication Number Publication Date
NO902909D0 NO902909D0 (no) 1990-06-29
NO902909L NO902909L (no) 1990-08-27
NO179164B NO179164B (no) 1996-05-13
NO179164C true NO179164C (no) 1996-08-21

Family

ID=22535596

Family Applications (1)

Application Number Title Priority Date Filing Date
NO902909A NO179164C (no) 1988-02-01 1990-06-29 Fremgangsmåte for fremstilling av et immunogenkonjugat

Country Status (10)

Country Link
EP (1) EP0399001B1 (no)
JP (1) JP2921574B2 (no)
AT (1) ATE109008T1 (no)
AU (1) AU634153B2 (no)
CA (2) CA1340958C (no)
DE (1) DE68917126T2 (no)
DK (1) DK174416B1 (no)
FI (1) FI104374B (no)
NO (1) NO179164C (no)
WO (1) WO1989006974A2 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2546544B2 (ja) * 1989-10-27 1996-10-23 アーチ ディベラップメント コーポレイション 免疫強化を促進するための方法と組成物
GB8924438D0 (en) * 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
CH683101A5 (de) * 1990-09-18 1994-01-14 Biotech Australia Pty Ltd T-Zellen-Epitope.
WO1993011157A1 (en) * 1991-11-27 1993-06-10 The Council Of The Queensland Institute Of Medical Research MALARIAL VACCINE AND PEPTIDES COMPRISING HUMAN T-CELL EPITOPE OF CIRCUMSPOROZOITE PROTEIN OF $i(P.VIVAX)
IL105503A (en) * 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
MX9304388A (es) * 1992-07-22 1994-03-31 Proteus Molecular Design Polopeptido sintetico y proceso para su fabricacion.
CA2141427C (en) * 1992-07-31 2008-07-22 Mohammed Anjam Khan Expression of recombinant fusion proteins in attenuated bacteria
US6261569B1 (en) 1992-08-27 2001-07-17 Deakin Research Limited Retro-, inverso- and retro-inverso synthetic peptide analogues
DK140992D0 (da) * 1992-11-24 1992-11-24 Ole Buchardt Fremgangsmaade til frembringelse af antistoffer mod haptener og andre b-celle-antigener, antistoffer opnaaet ved fremgangsmaaden og anvendelse af disse antistoffer til fremstilling af vacciner, isaer til veterinaermedicinsk brug
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
GB9401787D0 (en) 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccine compositions
AU7235794A (en) * 1993-07-30 1995-02-28 Medeva Holdings B.V. Vaccine compositions
GB2295394B (en) * 1994-01-31 1997-09-24 Medeva Holdings Bv DNA encoding a fusion protein comprising the C fragment of tetanus toxin
GB9401795D0 (en) * 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccines
WO1995024216A1 (en) * 1994-03-07 1995-09-14 Auckland Uniservices Limited Prevention of diabetes
US5773003A (en) * 1995-03-31 1998-06-30 Immulogic, Inc. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
DK1329226T3 (da) * 1995-03-31 2007-09-24 Xenova Res Ltd Haptenbærerkonjugater til anvendelse i behandling af stofmisbrug
US5843462A (en) * 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
AU2734397A (en) 1996-04-19 1997-11-12 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes
US7709002B1 (en) 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
DE19856052A1 (de) * 1998-12-04 2000-06-08 Deutsches Krebsforsch Konjugat zur Anreicherung in neuronalen Zellen
EP1343821A2 (en) 2000-11-09 2003-09-17 Immunolex Laboratories Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
US9555097B2 (en) 2006-02-23 2017-01-31 Era Biotech, S.A. Recombinant protein bodies as immunogen-specific adjuvants
US9358302B2 (en) * 2009-03-23 2016-06-07 The Brigham And Women's Hospital, Inc. Glycoconjugate vaccines
EP2418284A1 (en) 2010-08-13 2012-02-15 ERA Biotech, S.A. Protein body-inducing polypeptide sequences
EP2870974A1 (en) * 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
CN118662649A (zh) 2016-12-30 2024-09-20 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2020010000A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
EP4483896A2 (en) 2018-07-04 2025-01-01 Vaxcyte, Inc. Improvements in immunogenic conjugates
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates

Also Published As

Publication number Publication date
DK182990A (da) 1990-07-31
NO902909D0 (no) 1990-06-29
NO179164B (no) 1996-05-13
AU3065489A (en) 1989-08-25
EP0399001B1 (en) 1994-07-27
FI104374B (fi) 2000-01-14
CA1340958C (en) 2000-04-11
WO1989006974A3 (en) 1989-08-24
EP0399001A1 (en) 1990-11-28
AU634153B2 (en) 1993-02-18
DE68917126D1 (de) 1994-09-01
DE68917126T2 (de) 1995-02-02
JPH03502691A (ja) 1991-06-20
CA1340956C (en) 2000-04-11
DK182990D0 (da) 1990-07-31
WO1989006974A2 (en) 1989-08-10
NO902909L (no) 1990-08-27
FI903292A0 (fi) 1990-06-29
DK174416B1 (da) 2003-02-17
ATE109008T1 (de) 1994-08-15
JP2921574B2 (ja) 1999-07-19

Similar Documents

Publication Publication Date Title
NO179164C (no) Fremgangsmåte for fremstilling av et immunogenkonjugat
RU95105991A (ru) Конъюгат, вакцина, способы усиления иммуногенности, способы иммунизации
HK1143950A1 (en) Artificial t helper cell epitopes as immune stimulators for synthetic peptide immunogens
DE3380053D1 (en) Conjugates of haptenes and muramyl peptides having an immunogenic activity, and compositions containing them
NO974727L (no) Immunogene og immunostimulatoriske oligosakkarid sammensetninger og fremgangsmåter for fremstilling derav
US6165468A (en) Antigenic carbohydrate linked to an immunogenic carrier
UA27754C2 (uk) Комбінована педіатрична вакцина, спосіб одночасної комбінованої вакцинації
RU93048161A (ru) Комбинированная педиатрическая вакцина с усиленной иммуногенностью каждого вакционного компонента
ZA873922B (en) Method of preparation and use for feline leukemia virus antigens
AU6435596A (en) Pasteurella haemolytica type A-1 bacterin-toxoid vaccine
CO5241277A1 (es) Vacuna
WO1990015132A3 (en) Cloned treponema hyodysenteriae endoflagellar antigen

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees